Agent Phase Clinical trial no. Number of patients Objective response rate (ORR, %) Progression-free survival (PFS) Overall survival (OS) Reference Temsirolimus 2 NCT00087074 41 5 2 months – median time…
Patient population N Design Treatment arms Stratification factors Endpoints Results BOLERO-1 HER2+ ABC. First line 719 Randomization 2:1 Everolimus or placebo 10 mg/day + paclitaxel 80 mg/m2 days 1, 8, 15 + trastuzumab…
Drug Target Stage of development and indications Company mTOR Sirolimus (rapamycin) mTOR Approved for renal transplant, phase II/III trials for MM, NHL Pfizer Temsirolimus (CCI779) mTOR Approved for RCC and…
Pathway alteration Incidence Tumor type References mTOR overexpression 6/9 (67 %) pNET Shida et al. [11] Mutations in PTEN, TSC2, PIK3CA 10/68 (15 %) pNET Jiao et al. [12] Akt…
Fig. 1.1 Chemical structure of rapamycin and rapalogs. Rapalogs have the indicated O-substitutions at the C-40 position of rapamycin (red circle) Temsirolimus, formerly known as CCI-779; Torcel®, Wyeth Pharmaceuticals, now…
1. Serum LDH > 1.5 times the upper limit of normal 2. Hemoglobin level < lowest limit of normal 3. Corrected serum calcium level > 10 mg/dL (2.5 mmol/L) 4. Interval of less than 1 year…
Chromosomal defect Childhood tumor 1p del, 1p32-p36 del, double minutes Neuroblastoma 11p13 del, trisomy 18 Wilms’ tumor 13q14 del Retinoblastoma Osteosarcoma Trisomy 21 (Down syndrome) Leukemia Monosomy 7 Leukemia and…
Myeloproliferative neoplasms Chronic myelogenous leukemia, BCR-ABL1-positive Chronic neutrophilic leukemia Polycythemia vera Primary myelofibrosis Essential thrombocythemia Chronic eosinophilic leukemia, NOS Mastocytosis Myeloproliferative neoplasm, unclassifiable Myeloid and lymphoid neoplasms with eosinophilia and…
Fig. 5.1 An example of a PTT from Ref. [136]. Eight representative samples from de novo CRCs (T1 → T8), with truncating mutations identified by sequencing analysis. A substantial amount of normal…
Fig. 7.1 HCC evolution and its related molecular and immunological markers. CLD chronic liver disease, RN regenerative nodule, DN dysplastic nodule, N/N nodule-in-nodule [28] 7.4.1 Heat Shock Protein 70 (HSP70)…
